New treatments for irritable bowel syndrome in women.
The estimated prevalence of irritable bowel syndrome (IBS) in Western countries is 7-15%, with a female:male ratio of 2-2.5:1 in IBS patients who seek healthcare services; however, the female predominance is lower in the general population. IBS has a significant impact on health-related quality of life and is associated with a significant healthcare and economic burden. Management of IBS is comprised of general measures and pharmacologic and nonpharmacologic treatment. However, there are ongoing efforts to find more effective therapeutic approaches. As advancements in the understanding of the pathophysiology of IBS continue to grow, new and effective treatments with novel mechanisms of action that have the potential to improve relief of IBS symptoms over current treatments are likely to be developed. This article provides an overview of current and emerging therapies for IBS and also highlights sex and gender differences in clinical trials and treatment response.
Adeyemo
Mopelola A
MA
Center for Neurobiology of Stress, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, 11301 Wilshire Blvd, Building 115, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. madeyemo@mednet.ucla.edu
Chang
Lin
L
D001572:Benzofurans / Q000627:therapeutic use; D000529:Complementary Therapies / Q000379:methods; D004035:Diet Therapy / Q000379:methods; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000453:epidemiology / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D008297:Male; D016032:Randomized Controlled Trials as Topic; D017678:Sex Distribution
D001572:Benzofurans; D005343:Fibrinolytic Agents; D005765:Gastrointestinal Agents; C406662:prucalopride